- 23.05.2012, 10:03:49
- /
- OTE0005
Phase 3 Study Shows Efficacy is Maintained With lisdexamfetamine dimesylate (LDX) in Children and Adolescents With ADHD After at Least 6 Months of Treatment
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN
